Pharmacogenomics studies how a person’s DNA can influence medication response, including differences in drug metabolism, therapeutic effect, adverse reactions, and dose requirements. From an Ayurvedic perspective, its closest point of contact is deha prakriti, the constitutional assessment of an individual through stable physical, physiological, and psychological tendencies.

The most useful way to frame the intersection is not to equate a dosha directly with a gene. Rather, prakriti can be understood as a structured phenotypic classification that may help stratify people into biologically meaningful groups. Published work in ayurgenomics has explored whether Vata, Pitta, and Kapha-predominant individuals differ in gene expression, CYP2C19 polymorphisms, DNA methylation, HLA markers, and genome-wide SNP patterns. The clinical promise is personalization; the clinical caution is that prakriti assessment is not a substitute for formal pharmacogenomic testing or medical judgment.

The Foundational Hypothesis: Prakriti as a Phenotypic Framework

Classical Ayurveda describes prakriti as the natural constitution of a person, shaped by dosha predominance and expressed through anatomical build, appetite, digestion, bowel pattern, skin and hair features, heat or cold tolerance, sleep, activity, temperament, disease resistance, and other long-term traits. The classical framework includes seven prakriti categories: Vata, Pitta, Kapha, Vata-Pitta, Vata-Kapha, Pitta-Kapha, and balanced samadoshaja prakriti.

Ayurvedic texts place the formation of constitution at the beginning of life, using ideas such as the union of paternal and maternal reproductive factors, the condition of the uterus, time, maternal diet and lifestyle, and the predominance of dosha. This makes prakriti broader than genotype alone: it is closer to a constitutional phenotype that includes inherited, developmental, metabolic, and behavioral expression.

Published Human Studies Connecting Prakriti and Molecular Variation

The strongest material for this topic comes from small but influential human studies that used prakriti classification as a stratification method. These papers are best read as early translational research: they help define questions for personalized medicine, but they do not create a clinical dosing system.

Prasher et al. (2008): Gene Expression and Biochemical Correlates

Prasher and colleagues published “Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda” in the Journal of Translational Medicine. The study screened volunteers through prakriti assessment and selected 96 unrelated, ethnically matched healthy individuals classified as Vata, Pitta, or Kapha predominant. The work compared biochemical, hematological, and genome-wide expression patterns among these groups.

• The study selected 39 Vata, 29 Pitta, and 28 Kapha individuals after broader screening.
• The authors reported prakriti-linked differences in biochemical and hematological parameters.
• They reported 159 differentially expressed annotated genes in males and 92 in females, with limited overlap between the sex-stratified gene sets.
• The functional categories included transport, immune response, regulation of blood coagulation, and regulation of cyclin-dependent protein kinase activity.
• The study described itself as an early attempt to connect Ayurvedic phenotyping with modern biological measures.

This paper remains important because it treated prakriti as a reproducible phenotype rather than as a loose descriptive label. Its value for pharmacogenomics is indirect: it suggests that constitutional grouping may capture molecular differences relevant to metabolism and immune response, while leaving drug-specific decisions to future validation.

Ghodke, Joshi and Patwardhan (2011): CYP2C19 and Metabolic Variability

Ghodke, Joshi and Patwardhan examined CYP2C19 polymorphisms in 132 unrelated healthy subjects classified by prakriti. CYP2C19 is a clinically relevant drug-metabolizing enzyme, and the study directly addressed the Ayurvedic idea that Pitta and Kapha differ in metabolic tendency.

• The authors genotyped CYP2C19 using PCR-RFLP.
• The extensive-metabolizer genotype was reported as predominant in Pitta, with 91% of Pitta individuals in that category.
• The poor-metabolizer genotype was reported as highest in Kapha, at 31%, compared with 12% in Vata and 9% in Pitta.
• The CYP2C19 *2/*3 poor-metabolizer genotype was significantly associated with Kapha in the study population.

This is the most directly pharmacogenomic paper in the prakriti literature. It supports a focused research question: whether standardized prakriti assessment can enrich or stratify cohorts for CYP-related variability. It does not make prakriti a replacement for CYP2C19 genotyping when a medication decision requires pharmacogenomic evidence.

Rotti et al. (2015): DNA Methylation Signatures

Rotti and colleagues examined DNA methylation in phenotype-stratified Indian subjects. After a larger prakriti assessment process, the study analyzed 147 healthy male individuals aged 20–30 years who were classified into Vata, Pitta, or Kapha groups.

• The authors reported differentially methylated regions in CpG islands, CpG shores, promoters, untranslated regions, and gene bodies.
• Pitta showed distinct promoter and gene-body methylation signals.
• Vata and Kapha groups also showed prakriti-associated methylation patterns.
• The study validated selected genes including LHX1 for Vata, SOX11 for Pitta, and CDH22 for Kapha.
• CDH22 was discussed in relation to BMI in the Kapha group.

This work adds an epigenomic layer to the ayurgenomics discussion. It is especially relevant because prakriti is described in Ayurveda as a stable constitutional pattern, while methylation reflects regulation of gene expression rather than only fixed DNA sequence.

Govindaraj et al. (2015): Genome-Wide SNP Analysis and PGM1

Govindaraj and colleagues published a genome-wide SNP analysis correlating Ayurveda prakriti in Scientific Reports. The study began with 3,416 assessed individuals and used 262 well-classified male subjects for genome-wide analysis with Affymetrix 6.0 arrays.

• The authors used genome-wide SNP data to examine differences among Vata, Pitta, and Kapha groups.
• They reported 52 markers for genotype-phenotype correlation and 28 genic SNPs among the relevant markers.
• A notable association was reported between Pitta prakriti and PGM1.
• PGM1 is involved in metabolic pathways such as glycolysis, gluconeogenesis, galactose metabolism, purine metabolism, and starch and sucrose metabolism.

The PGM1 finding is meaningful because Pitta is classically linked with digestion, transformation, heat, and metabolism. The proper interpretation is a biologically plausible correlation within a defined study design, not a universal genetic definition of Pitta.

Clinical Implications: A Research Bridge, Not a Stand-Alone Dosing System

The practical attraction of prakriti-guided personalization is clear: Ayurveda already uses constitutional assessment to individualize diet, lifestyle, herbs, therapies, and preventive guidance. Pharmacogenomics similarly seeks to individualize care by identifying genetic variation that affects medication response. The responsible bridge between the two is to use prakriti as a phenotyping layer that may help generate, refine, or test personalized-medicine hypotheses.

In routine medical care, however, medication decisions must not be made from prakriti alone. CYP2C19, for example, is relevant to medicines such as proton pump inhibitors, clopidogrel, and some antidepressants, but clinical interpretation depends on the specific drug, the patient’s genotype, diagnosis, age, organ function, other medicines, treatment goal, and prescribing guidance. Prakriti may eventually help identify who should be prioritized for formal testing or closer monitoring, but the current role is supportive and investigational.

How Prakriti Could Assist Personalization

A careful prakriti-informed model would keep Ayurvedic constitution and modern pharmacogenomics in their proper domains. Prakriti can organize whole-person traits, while pharmacogenomic testing can identify specific genetic variants relevant to particular drugs.

A Prakriti-Informed Research Framework

The most rigorous path is to test prakriti alongside established clinical and genomic variables instead of treating it as a replacement for them. A future study design could combine standardized prakriti assessment, blinded practitioner evaluation, ancestry and demographic data, diet and lifestyle records, laboratory measures, pharmacogenomic panels, and prospective treatment outcomes.

• Use validated prakriti questionnaires and independent clinician assessment to reduce classification error.
• Record age, sex, ancestry, region, diet, disease status, organ function, and concurrent medicines.
• Genotype clinically relevant pharmacogenomic markers, including CYP enzymes where appropriate.
• Follow medication response, adverse effects, dose adjustments, and treatment outcomes prospectively.
• Measure whether prakriti adds predictive value beyond standard pharmacogenomic and clinical variables.

This framework preserves the Ayurvedic insight that patients differ constitutionally while respecting the modern requirement that drug-specific decisions need drug-specific evidence.

Limitations and Necessary Caution

The prakriti-genomics field is intellectually important, but the current human literature is still early-stage. Its findings are best used to shape further research and not to create simplified rules such as “Vata needs one dose,” “Pitta needs another,” or “Kapha needs a higher dose.”

• Sample size: The major studies used carefully selected cohorts such as 96 subjects, 132 subjects, 147 male subjects, or 262 male subjects. These are valuable for hypothesis formation, but not enough for broad clinical rules.
• Population specificity: Several cohorts were drawn from specific Indian populations and may not generalize to every region, ancestry group, age group, or mixed-prakriti population.
• Classification complexity: Prakriti assessment includes many traits and can vary by tool, practitioner, and the dominance of single or mixed dosha patterns.
• Probabilistic associations: A group-level association does not determine an individual person’s CYP status, adverse-effect risk, or medication response.
• Holistic versus single-gene mapping: Prakriti is a multi-dimensional constitutional framework, while pharmacogenomic markers are often drug- and pathway-specific.

These limitations do not weaken the value of the research direction; they define the discipline needed to move from correlation to clinical usefulness.

The Path Forward

Ayurgenomics can mature by combining classical Ayurvedic phenotyping with modern study design. The strongest future work would be multi-center, adequately powered, transparent in prakriti classification, and linked to real clinical outcomes rather than only molecular differences.

• Large multi-region cohorts across diverse Indian and global populations.
• Standardized prakriti tools with reproducibility testing between practitioners and questionnaires.
• Integrated omics work combining genomics, transcriptomics, epigenomics, metabolomics, microbiome data, and clinical parameters.
• Prospective medication-response studies for specific drugs with known pharmacogenomic relevance.
• Independent replication before any prakriti-based medication guidance is used in routine care.

The meeting point of Ayurveda and pharmacogenomics is not a shortcut around modern testing; it is a possible enrichment of personalized medicine through a deep constitutional phenotype. If validated at scale, prakriti may help clinicians and researchers think about individuality in a more integrated way. For related reading, see Reverse Pharmacology in Ayurveda and Ayurvedic Herbs and Cytochrome P450 Enzymes.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Do not start, stop, reduce, increase, or substitute any medication based on prakriti, dosha assessment, CYP status, or online information alone. Consult a licensed physician, clinical pharmacologist, qualified Ayurvedic practitioner, or other qualified healthcare provider for individualized care. Formal pharmacogenomic testing, when needed, should be ordered and interpreted by qualified professionals in the context of the specific medicine and patient.

References

1. Genome (genome.gov)
2. MedlinePlus
3. FDA
4. Charaka Samhita — Deha prakriti
5. Charaka Samhita — Khuddika Garbhavakranti Sharira
6. Link (link.springer.com)
7. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
8. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
9. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts (2012), PubMed
10. DNA methylation analysis of phenotype specific stratified Indian population (2015), PubMed
11. Association between depressive symptoms, weight and treatment outcome in a very large anorexia nervosa sample (2016), PubMed
12. Nature (nature.com)
13. Genomicseducation (genomicseducation.hee.nhs.uk)

Ayurveda individualizes treatment, but Prakriti alone does not reliably predict how a particular person will metabolize or respond to a conventional medicine. Molecular studies have identified preliminary associations between selected constitutional groups and gene expression, genetic variants, DNA methylation, and CYP2C19 genotypes; these findings remain exploratory and cannot replace validated pharmacogenetic testing, clinical examination, or therapeutic monitoring.

The interdisciplinary field commonly called Ayurgenomics examines whether carefully assessed Ayurvedic phenotypes correspond to measurable biological patterns. Its most useful contribution may be the development of testable questions about human variability. Its present findings do not justify assigning a drug, changing a prescription dose, or predicting an adverse reaction from dosha constitution alone.

Understanding Prakriti as an Ayurvedic Constitution

Prakriti is the individual constitution described in Ayurveda as being established through factors operating around conception. Classical descriptions recognize seven major deha-prakriti groupings: Vata, Pitta, Kapha, the three dual-dosha combinations, and sama-doshaja, in which the doshas are comparatively balanced. Prakriti is treated as a constitutional baseline rather than a diagnosis of disease.

Traditional assessment is multidimensional. It considers recurring characteristics such as body build, movement, appetite, digestion, temperature tolerance, skin and hair qualities, sleep, endurance, speech, emotional tendencies, and habitual patterns. A constitution should therefore be assessed through a structured clinical interview and observation rather than a brief personality quiz or a single physical feature.

Prakriti and Vikriti Are Not Interchangeable

Vikriti denotes the person’s present departure from balance. Symptoms, dosha aggravation, digestive disturbance, tissue involvement, season, diet, medicines, age, environment, and the stage and strength of disease may alter the current presentation without changing the underlying constitutional classification. Ayurvedic management is consequently based on the present clinical state as well as Prakriti.

Prakriti Is One Part of a Larger Examination

Charaka Samhita’s tenfold examination in Vimanasthana includes Prakriti and Vikriti together with tissue quality, bodily compactness, measurements, suitability or adaptation, mental strength, digestive and assimilative capacity, exercise capacity, and age. This framework prevents constitutional typing from becoming the sole basis of treatment and helps the physician judge the patient’s strength and the appropriate intensity of therapy.

What Ayurgenomics Studies Have Reported

Ayurgenomics studies have generally selected people who display relatively clear Vata-, Pitta-, or Kapha-predominant characteristics. Researchers have then compared molecular measurements between those groups. This design can identify group-level associations, but it does not establish that a constitutional label determines a person’s genotype, drug concentration, clinical response, or risk of toxicity.

The 2005 HLA-DRB1 Study

A study of 76 healthy participants compared 14 HLA-DRB1 alleles across constitution groups. In that sample, HLA-DRB1*02 was absent from the Vata group, HLA-DRB1*13 was absent from the Kapha group, and HLA-DRB1*10 occurred more frequently in Kapha than in the other predominant groups. The small sample and multiple allele comparisons make these findings hypothesis-generating rather than clinically diagnostic.

HLA-DRB1 associations must not be confused with pharmacogenetic testing for other HLA loci. The study did not establish that Pitta constitution predicts drug hypersensitivity, nor did it examine the clinically actionable HLA-B variants used with allopurinol or carbamazepine.

The 2008 Gene-Expression Study

A 2008 Journal of Translational Medicine study, indexed as PMID 18782426, evaluated 96 unrelated healthy adults classified as 39 Vata, 29 Pitta, and 28 Kapha. The investigators reported differences in biochemical measurements and pooled peripheral-blood gene-expression profiles. Functional categories included transport, immune response, coagulation, and regulation of cellular processes.

The microarray analysis identified 159 differentially expressed genes in the male comparison and 92 in the female comparison, with only five genes shared between the two lists. Eighteen genes were subsequently assessed by quantitative PCR and eight followed the corresponding microarray pattern. These results indicate possible biological heterogeneity among highly selected constitution groups, but they do not constitute a pharmacogenomic dosing rule.

The 2011 CYP2C19 Association

A study of 132 unrelated healthy participants examined CYP2C19 genotypes in relation to Prakriti. Extensive-metabolizer genotypes were more prominent in the Pitta group, whereas poor-metabolizer genotypes, particularly CYP2C19*2/*2, were more frequent in the Kapha group. The Vata group was not the group most strongly associated with poor-metabolizer alleles.

This was a genotype-frequency association in a limited cohort. It did not demonstrate that all Kapha-predominant people are poor metabolizers or that a Pitta-predominant person will metabolize every CYP2C19 substrate rapidly. CYP2C19 phenotype depends on the person’s actual diplotype and may also be modified by interacting medicines, illness, adherence, and other clinical factors.

The 2015 DNA-Methylation Analysis

A separate investigation selected 147 healthy young men after screening a much larger population and compared DNA-methylation patterns among predominant Prakriti groups. The analysis reported group-associated methylation signals involving LHX1 in Vata, SOX11 in Pitta, and CDH22 in Kapha. Methylation near CDH22 in the Kapha group was also examined in relation to body-mass index.

DNA methylation is influenced by cell composition, age, exposures, nutrition, and other environmental conditions. A cross-sectional methylation signature therefore cannot be interpreted as a permanent constitutional gene or as proof that a particular dosha causes a metabolic disease.

The 2015 Genome-Wide SNP Analysis

A genome-wide study published in Scientific Reports assessed 262 well-classified healthy men selected after screening 3,416 volunteers. It identified 52 single-nucleotide polymorphisms whose frequencies differed among the three predominant groups at the study’s specified significance threshold. The analysis highlighted an association involving PGM1 and the Pitta phenotype and compared the selected groups with ancestry information from Indian population datasets.

The reported units were 52 genetic variants, not 52 genes. The analysis supported the possibility that constitution groups captured some reproducible phenotypic structure in that cohort, but it did not validate a commercial genetic test for Prakriti or establish a drug-response algorithm.

Verified Evidence Map

The principal human studies differ substantially in design, sample selection, biological measurement, and clinical relevance. Reading them together requires separating molecular association from demonstrated treatment utility.

Where Pharmacogenomics Is Clinically Actionable

Clinical pharmacogenomics uses a patient’s directly measured genotype together with drug-specific guidelines. The result applies to a defined gene-drug pair, not to every medicine and not to an entire constitutional category. Actionable recommendations are developed from pharmacokinetic, clinical-outcome, and adverse-reaction data and are periodically updated as new evidence is evaluated.

CYP2C19, Clopidogrel, and Proton-Pump Inhibitors

CYP2C19 genotype can affect formation of clopidogrel’s active metabolite and the probability of achieving adequate antiplatelet activity. Clinical Pharmacogenetics Implementation Consortium guidance provides genotype-based recommendations for appropriate cardiovascular and neurovascular indications. Several proton-pump inhibitors are also substantially metabolized through CYP2C19, and CPIC guidance addresses how metabolizer status may affect exposure, efficacy, and adverse effects.

A dosha assessment cannot identify a CYP2C19 diplotype. When CYP2C19 status could materially alter treatment, the appropriate tools are a validated laboratory test, the medicine’s indication, the patient’s medical history, interacting drugs, and a recognized pharmacogenomic guideline.

HLA-B and Severe Cutaneous Reactions

HLA-B*58:01 is associated with a markedly increased risk of severe cutaneous adverse reactions from allopurinol, and genotype-informed guidance recommends avoiding allopurinol in a person who tests positive. For carbamazepine, recommendations consider HLA-B*15:02 and HLA-A*31:01 because of their associations with serious cutaneous reactions in relevant populations.

These are specific allele-drug relationships. The earlier HLA-DRB1 constitution study did not test these alleles and cannot be used as a preliminary replacement for HLA-B or HLA-A genotyping. Pitta constitution, skin sensitivity, heat intolerance, or a history of inflammatory symptoms does not establish the presence or absence of an actionable HLA allele.

Why Prakriti Cannot Substitute for Genotyping

People within the same Prakriti category remain genetically diverse, while the same pharmacogenetic allele can occur in more than one constitutional group. An association detected between two groups changes only the estimated frequency of a marker within the studied sample. It does not reveal which individual carries that marker, and it may change when ancestry, sex, age, recruitment criteria, or classification methods differ.

The 2017 phenytoin study illustrates this distinction. Among 351 patients receiving phenytoin monotherapy, Prakriti was not associated with CYP2C9 or CYP2C19 genotype, measured phenytoin concentration, or metabolic phenotype. CYP2C9*1/*3, however, was associated with toxic concentrations. Direct pharmacogenetic information was therefore more relevant than constitution for this specific drug.

Drug response also depends on renal and hepatic function, body composition, age, pregnancy, diet, adherence, smoking, interacting medicines, formulation, dose, disease severity, and the therapeutic target. None of these variables should be replaced by a constitutional inference.

Ayurvedic Personalization Extends Beyond Genomics

Ayurvedic individualization is broader than assigning one of three dosha labels. The physician examines the disorder, the patient’s present dosha and tissue state, digestive and assimilative capacity, strength, adaptation to diet and habits, mental resilience, age, habitat, season, and prior response to treatment. This is a clinical framework for matching the intensity and form of therapy to the person’s condition.

Constitution Does Not Dictate a Universal Dose

Classical reasoning permits mild, moderate, or stronger treatment according to the patient’s strength, disease strength, digestive capacity, age, and suitability. It does not support a universal rule that every Vata person must receive a low dose, every Pitta person must receive hepatotoxicity monitoring, or every Kapha person clears lipophilic medicines slowly. Those claims require medicine-specific clinical measurements.

Medicine, Preparation, Vehicle, and Timing

Ayurvedic prescribing distinguishes the medicinal substance from its preparation, dose, timing, route, and anupana, the accompanying vehicle. These choices are made in relation to the patient and disorder. They should not be converted into untested CYP, HLA, lipid-metabolism, or insulin-signalling claims merely because a traditional characteristic appears conceptually similar to a modern biomedical pathway.

Responsible Integration in Clinical Practice

Ayurveda and pharmacogenomics can be used together when each remains within its validated scope. Ayurvedic assessment can contribute a structured account of constitution, current imbalance, digestion, diet, routines, tolerance, and treatment preferences. Pharmacogenomics can answer selected questions about defined genetic variants and medicines.

A Safe Clinical Sequence

A practical integrative sequence begins with diagnosis and medication review, uses pharmacogenetic testing when supported by a recognized guideline, and adds qualified Ayurvedic assessment without treating Prakriti as a laboratory result.

1. Confirm the diagnosis, treatment indication, current medicines, allergies, organ function, and previous adverse reactions.
2. Identify whether an established gene-drug guideline applies to the medicine being considered.
3. Order a validated genetic test when its result is likely to affect prescribing or monitoring.
4. Assess Prakriti and Vikriti through a trained Ayurvedic practitioner as part of the broader clinical picture.
5. Review herbs, supplements, formulations, and dietary practices for interactions and product-quality concerns.
6. Monitor symptoms, laboratory values, efficacy, and adverse effects rather than assuming a response from constitution.

Herb-Drug Safety

Herbal products can alter absorption, sedation, blood pressure, glucose control, coagulation, or the activity of drug-metabolizing enzymes and transporters. Risks also depend on botanical identity, processing, contamination, dose, and the other ingredients in a formulation. Anyone taking prescription medicines should discuss Ayurvedic products with a qualified Ayurvedic practitioner and the prescribing healthcare professional, especially before surgery, during pregnancy, or when using anticoagulants, antiepileptics, immunosuppressants, or medicines with a narrow therapeutic range.

Limitations of the Current Evidence

Most molecular Prakriti studies have used small, highly selected groups representing relatively clear single-dosha phenotypes. Several enrolled only men or restricted participants to narrow age ranges. Such selection may help detect biological contrasts, but it represents only part of clinical practice, where dual-dosha constitutions and changing disease states are common.

Assessment methods also vary. A 2025 critical review identified 64 distinct Prakriti-assessment instruments, while only 20 had undergone some form of validation and none satisfied the review’s complete validation framework. Differences in questionnaires, examiner judgment, scoring rules, language, and thresholds make independent comparison and replication difficult.

Many studies are cross-sectional and examine numerous molecular variables simultaneously. Their findings require correction for multiple comparisons, replication in independent cohorts, appropriate ancestry controls, transparent preregistration, and confirmation with clinically meaningful outcomes. A molecular difference between groups is not equivalent to improved efficacy, reduced toxicity, or a validated prescribing recommendation.

Future Directions for Ayurgenomics

Future studies should use multicentre recruitment, standardized and independently tested constitution assessment, diverse ancestry groups, adequate representation of women and mixed constitutions, blinded phenotype assignment, and prespecified statistical plans. Replication cohorts should be included before a molecular marker is described as characteristic of a Prakriti group.

Drug-response studies should measure actual pharmacokinetic or clinical endpoints: drug and metabolite concentrations, treatment success, adverse reactions, laboratory toxicity, and validated patient outcomes. Prakriti-stratified findings should then be compared with direct genotyping and ordinary clinical predictors to determine whether constitutional assessment adds useful information beyond established practice.

Genomics, transcriptomics, epigenomics, proteomics, metabolomics, and microbiome analysis may help characterize biological diversity within and between constitutional groups. These methods are most informative when they test clearly defined hypotheses rather than assigning a single gene, enzyme, immune pathway, or disease tendency to an entire dosha.

Conclusion

Prakriti is an authentic Ayurvedic framework for understanding constitutional variation and tailoring clinical assessment. Human studies have reported associations involving HLA-DRB1 alleles, blood gene-expression profiles, CYP2C19 genotypes, DNA methylation, and genome-wide variants. The studies do not establish that dosha constitution can predict an individual’s response to conventional drugs or replace direct pharmacogenetic testing.

The most responsible integration is complementary: use Prakriti and Vikriti within a complete Ayurvedic examination, and use genotype-based recommendations only for gene-drug relationships supported by validated testing and clinical guidance. Prescription doses should never be started, stopped, or changed on the basis of dosha constitution without consultation with the prescribing healthcare professional.

This article is for educational purposes. Prakriti assessment, pharmacogenetic interpretation, herbal prescribing, and changes to conventional medication should be undertaken with appropriately qualified Ayurvedic and medical practitioners.

References

1. Charaka Samhita — Deha prakriti
2. Charaka Samhita — Rogabhishagjitiya Vimana
3. Frontiersin (frontiersin.org)
4. Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda (2005), PubMed
5. Link (link.springer.com)
6. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda (2008), PubMed
7. Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability (2011), PubMed
8. Link (link.springer.com)
9. Nature (nature.com)
10. Genome-wide analysis correlates Ayurveda Prakriti (2015), PubMed
11. A prospective study to assess the association between genotype, phenotype and Prakriti in individuals on phenytoin monotherapy (2017), PubMed
12. Clinpgx (clinpgx.org)
13. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing (2021), PubMed
14. Clinpgx (clinpgx.org)
15. Clinpgx (clinpgx.org)
16. Ayurgenomics for stratified medicine: TRISUTRA consortium initiative across ethnically and geographically diverse Indian populations (2017), PubMed
17. Recapitulation of Ayurveda constitution types by machine learning of phenotypic traits (2017), PubMed
18. Pharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shift (2015), PubMed
19. Frontiersin (frontiersin.org)
20. Whole Exome Sequencing in Healthy Individuals of Extreme Constitution Types Reveals Differential Disease Risk: A Novel Approach towards Predictive Medicine (2022), PubMed
21. EGLN1 involvement in high-altitude adaptation revealed through genetic analysis of extreme constitution types defined in Ayurveda (2010), PubMed